RESEARCH ARTICLE

The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo

Natalie C. G. Kwai¹, William Nigole¹, Ann M. Poynten², Christopher Brown³, Arun V. Krishnan¹*

¹ Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, ² Department of Endocrinology, Prince of Wales Hospital, Sydney, Australia, ³ National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia

* arun.krishnan@unsw.edu.au

Abstract

Objectives

Diabetic peripheral neuropathy (DPN) is a common and debilitating complication of diabetes mellitus. Treatment largely consists of symptom alleviation and there is a need to identify therapeutic targets for prevention and treatment of DPN. The objective of this study was to utilise novel neurophysiological techniques to investigate axonal function in patients with type 2 diabetes and to prospectively determine their relationship to serum lipids in type 2 diabetic patients.

Methods

Seventy-one patients with type 2 diabetes were consecutively recruited and tested. All patients underwent thorough clinical neurological assessments including nerve conduction studies, and median motor axonal excitability studies. Studies were also undertaken in age matched normal control subjects (n = 42). Biochemical studies, including serum lipid levels were obtained in all patients. Patient excitability data was compared to control data and linear regression analysis was performed to determine the relationship between serum triglycerides and low density lipoproteins and excitability parameters typically abnormal in type 2 diabetic patients.

Results

Patient mean age was 64.2±2.3 years, mean glycosylated haemoglobin (HbA1c%) was 7.8±0.3%, mean triglyceride concentration was 1.6±0.1 mmol/L and mean cholesterol concentration was 4.1±0.2mmol/L. Compared to age matched controls, median motor axonal excitability studies indicated axonal dysfunction in type 2 diabetic patients as a whole (T2DM) and in a subgroup of the patients without DPN (T2DM-NN). These included reduced percentage threshold change during threshold electrotonus at 10–20ms depolarising currents (TEDt10–20ms)(controls 68.4±0.8, T2DM63.9±0.8, T2DM-NN64.8±1.6%, P<0.05) and superexcitability during the recovery cycle (controls-22.5±0.9, T2DM-17.5±0.8, T2DM-NN-
17.3±1.6%, \( P < 0.05 \). Linear regression analysis revealed no associations between changes in axonal function and either serum triglyceride or low density lipoprotein concentration when adjusted for renal function, a separate risk factor for neuropathy development. Our findings indicate that acutely, serum lipids do not exert an acute effect on axonal function in type 2 diabetic patients: TEd(10–20ms)(1.2(-1.4,3.8); \( P = 0.4 \)) and superexcitability (2.4 (-0.05, 4.8); \( P = 0.06 \)).

Conclusions
These findings suggest that serum triglyceride levels are not related to axonal function in type 2 diabetic patients. Additional pathogenic mechanisms may play a more substantial role in axonal dysfunction prior to DPN development.

Introduction
Diabetes mellitus is frequently complicated by the development of a length-dependent peripheral neuropathy (DPN). DPN is characterised by debilitating symptoms such as pain, paraesthesia and burning which can lead to reduced quality of life [1, 2]. Currently there is no cure and management primarily consists of symptom relief [3]. There is therefore a need for early diagnosis and identification of etiological factors which underlie DPN development and that can provide avenues for preventative care.

Traditionally, emphasis has been placed on hyperglycaemia as the primary etiological factor in DPN development. However, clinical trials administering stringent glucose control regimens have yielded disparate outcomes in terms of DPN development between type 1 and type 2 diabetic patients [4–7]. These findings have alluded to differential mechanisms of neuropathy development between type 1 and type 2 diabetes [8]. Specifically, type 2 diabetes often emerges in the setting of the metabolic syndrome, and thus the pathogenesis of DPN development in this cohort may be influenced by features of metabolic syndrome that are otherwise not present in type 1 diabetes [9]. Dyslipidemia is a prominent feature in the type 2 diabetic population and large epidemiological studies have implicated hyperlipidemia as a predictor of more severe neuropathy [10] although the mechanisms are still not well understood.

Previous studies in type 2 diabetic patients have revealed alterations in peripheral axonal function using axonal excitability techniques, which provide information on the behaviour of axonal ion channels and energy-dependent pumps and exchangers [11]. Previous studies in DPN have demonstrated changes in excitability parameters possibly due to dysfunction of the energy-dependent Na+/K+ pump [12–14]. The underlying basis for the alterations in axonal excitability in DPN patients remains unclear and previous investigations have suggested possible associations with estimated glomerular filtration rates (eGFR) [12, 15, 16], HbA1c% [15–18] and serum triglyceride levels [16]. However, the majority of these investigations were undertaken in small cohorts and changes were evaluated using post-hoc analysis rather than prospectively. Furthermore, association between excitability changes and biochemical parameters did not account for potential confounders such as baseline neuropathy severity and alterations in renal function [11].

Therefore the aim of the present study was to prospectively assess the potential contribution of serum metabolic parameters, specifically triglyceride and low-density-lipoprotein (LDL) levels, to altered excitability profiles in patients with type 2 diabetes. Statistical analysis was undertaken using linear regression, adjusted for renal function and severity of existing neuropathy.
Research Design and Methods

Clinical neurological assessments and axonal excitability studies were conducted in 98 consecutive type 2 diabetic patients recruited from the Diabetes Centre at Prince of Wales Hospital in Sydney. Patients who were receiving neuropathic pain treatment or who had a prior history of neuropathy due to other causes were excluded from the study. A total of 71 type 2 diabetic patients were subsequently enrolled. These analyses were conducted in R (Version 3.1.0) by a biostatistician (C.B.). While no specific power calculation was undertaken, the sample size was based on a previous study of 30 diabetic subjects by Bae and colleagues which demonstrated an association between triglycerides and axonal function on post-hoc analysis but which did not control for changes in renal function [16]. All subjects gave written informed consent in accordance with the Declaration of Helsinki, and the study was approved by the South Eastern Sydney Area Health Service and the University of New South Wales Research Ethics committees (HREC#14/012). Pathology studies were undertaken at the South Eastern Area Laboratory Services.

Clinical assessments, neuropathy and renal disease staging

A comprehensive neurological assessment was conducted in all patients and neuropathy severity was graded according to a modified version of the Total Neuropathy Score (TNS) [19] which has been previously used in a number of large cohort studies in diabetes [12, 20]. The TNS is a composite score of 8 categories which assess extent and severity of sensory and motor symptoms, assessment of deep tendon reflexes, muscle strength, vibration sensibility (128 Hz tuning fork), pinprick sensation (Neurotip™, Owen Mumford, United Kingdom) and tibial and sural nerve amplitudes (Medelec Synergy system, Oxford Instruments, United Kingdom). Each category was scored from 0–4 (0 = no dysfunction, 4 = severe dysfunction) and summed to give a total score from 0–32 (32 = maximum dysfunction). The TNS was further subdivided into total neuropathy grades (TNG); TNG 0 = TNS 0–1, TNG 1 = TNS 2–8, TNG 2 = TNS 9–16, TNG 3 = 17–24 and TNG 4 = TNS 25–32 [19]. Severity of chronic kidney disease (CKD) was quantified in stages according to eGFR. Specifically, CKD stage 1: ≥90, CKD stage 2: 60–89, CKD stage 3: 20–59 and CKD stage 4: <20mL/min/1.73m².

Assessment of axonal ion channel properties

Axonal excitability studies were undertaken in all patients [21]. These studies involved stimulating the median nerve at the wrist and measuring the compound muscle action potential (CMAP) of abductor pollicis brevis using surface electrodes (Unomedical, Bikerod, Denmark). Parameters of axonal excitability were derived using QTRAC automated software (Digitimer, London, UK) which specifically applied the TRONDNF protocol [22]. QTRAC software allowed the rapid acquisition of a number of excitability parameters which are derived from five distinct testing paradigms; (i) stimulus response behaviour, (ii) strength duration relationship, (iii) threshold electrotonus, (iv) recovery cycle and (v) current threshold relationship.

Stimulus response curves were derived by applying a current of 1ms duration and increasing the intensity until the maximal CMAP response was obtained. Subsequently, a target for the remaining test paradigms was established (~40% of the maximum CMAP). The stimulus intensity required to reach this target was termed “threshold”. Strength-duration-time-constant (SDTC) was obtained by plotting the relationship between stimulus strength and stimulus duration using at least two duration points. This constant was determined to be the ratio of threshold current increase to stimulus duration decrease, and partly reflects the activity of nodal persistent Na⁺ conductances [23], which are thought to underlie the generation of ectopic neuropathic symptoms [24, 25]. Threshold electrotonus was determined by plotting
percentage change of threshold when 1ms test impulses were delivered during and after 100ms subthreshold conditioning currents of +40% (TEd) and -40% (TEh) control threshold. This paradigm provides information regarding internodal properties and overall axonal membrane potential [11]. The recovery cycle assesses the recovery of axonal conduction following a supramaximal stimulus. The percentage of threshold change in the recovery cycle was measured by varying the delay between the test impulse (1ms of threshold current) and a conditioning stimulus that was supramaximal. [22]. Current threshold relationship was obtained by plotting the change in threshold with 1ms test impulses post the delivery of 200ms depolarising and hyperpolarising conditioning currents (+50 to -100ms). This paradigm provides information on the rectifying properties of the internodal region of the axon [11].

Statistical analysis
SPSS statistics software v.20 (IBM, Chicago, IL) was used for group comparisons. Specifically, to investigate differences in axonal excitability parameters between patient data and age and sex matched normal controls (n = 42), normality of all data was first assessed using the Shapiro Wilk test. Whole group patient data (T2DM) was then compared to normal control data using either an independent t test or Mann Whitney U test depending on the outcome of the normality assessment. To determine axonal excitability alterations in non-neuropathic patients, a subgroup of the T2DM group with no neuropathy (T2DM-NN) was compared to normal control data using either an independent t test or Mann Whitney U test dependent on normality of data. Criteria for inclusion in the T2DM-NN was a TNG score of 0, indicating there were no signs and symptoms of neuropathy in addition to normal nerve conduction study results.

To determine the relationship between triglyceride levels and axonal function, we performed linear regression adjusting for renal function and neuropathy severity in the whole cohort (T2DM). We examined eight parameters of interest which routinely show abnormality in type 2 diabetic patients and progressively alter with the development of DPN [12]: TEh(90–100ms), TEd(10–20ms), SDTC (ms), superexcitability, subexcitability, S2 accommodation, and superexcitability at 7ms. We separately evaluated each parameter for association with triglycerides (TG) using linear regression adjusted for neuropathy TNS and eGFR. To evaluate sensitivity of analyses to categorisation of the confounders, a secondary analysis was conducted adjusting for neuropathy severity (measured by TNS and TNG) and severity of kidney disease (eGFR and CKD stage). 95% confidence intervals were computed for all estimates and p-values <0.05. This analysis was repeated for the low density lipoprotein (LDL) outcome.

Results
A total of 71 patients with type 2 diabetes were assessed. Patient clinical characteristics are provided in Table 1. Patients mean age was 64.2±2.3 years and had slightly elevated HbA1c% and serum lipids. eGFR indicated on average mild renal impairment in the cohort, denoted by stage 2 (60–89ml/min/1.73m²). Total Neuropathy Scores (TNS) from the patients revealed that 42% of patients (n = 51) had clinical signs and symptoms of DPN, which is consistent with previous studies in the literature [26].

Excitability was abnormal between patients and age matched controls
Median axonal excitability parameters obtained from the patients were compared to age and sex matched normal control data, revealing multiple abnormalities in median axonal excitability properties (Table 2). These were limited primarily to threshold electrotonus and recovery cycle parameters and were consistent with findings in previous studies performed in patients with DPN [12]. Critically, differences were seen in both whole group data taken from the type
2 diabetic patients (T2DM) and in a subset of this patient cohort without signs or symptoms of DPN (T2DM-NN).

Specifically, reduced percentage threshold change was noted during the threshold electrotonus paradigm in response to depolarising (TEd) and hyperpolarising (TEh) currents of varying delays (Table 2 and Fig 1A).

During the recovery cycle paradigm (Table 2 and Fig 1B), reductions were most notable during superexcitability, with corresponding alterations at 5 and 7 ms, and subexcitability. Relative refractory periods were not significantly different between controls and either T2DM or T2DM-NN group data. During the strength duration paradigm, SDTC appeared longer in the T2DM group but this was not statistically significant. Cumulatively, the changes noted in threshold electrotonus and recovery cycle parameters are consistent with depolarisation of the axonal membrane potential [14, 27, 28].

Axonal excitability was not associated with serum triglyceride and LDL

Serum triglyceride and LDL levels were obtained in all 71 participants. Triglycerides ranged from 0.4 to 5.5 mmol/L, LDL levels ranged from 0.6 to 4.6 mmol/L and eGFR ranged from 26 to 137 mL/min/1.73 m². There were no associations between axonal excitability parameters and serum triglycerides (Table 3 and Fig 2). Notably, no associations were observed in the sensitivity analysis which was adjusted for neuropathy severity (TNG) and nephropathy severity (CKD stage) (Table 3).

Similarly, in the analysis of LDL and axonal excitability parameters (Table 4), no notable associations were observed.

Discussion

The present study was undertaken to prospectively evaluate the association between serum triglyceride and LDL levels and changes in axonal function in a type 2 diabetic cohort. Statistical analyses were undertaken and adjusted for confounders (neuropathy severity and renal function) which have previously been associated with alterations in axonal function in a T2DM cohort [12, 29, 30]. Our study indicates that after accounting for these variables, there were no significant associations between altered serum triglyceride or LDL concentration and changes in axonal function in T2DM patients. It should be noted that while these studies were undertaken prospectively, a significant percentage of the cohort had serum triglyceride levels that
were within the normal range and previous work has suggested that the neurotoxic effects are mediated by hypertriglyceridemia [31], which may explain the lack of association in the present study. A limitation of the study was the lack of stratification for duration of diabetes which is a risk factor for neuropathy development [1]. Furthermore, we did not stratify for total cholesterol levels or the duration of their presence. This is of potential importance as both low HDL and opposing high LDL cholesterol levels have been previously associated with neuropathy development [32].

The pattern of change in axonal function noted in the present study is consistent with previous investigations undertaken in type 2 diabetic patients [12,14,17,26]. Given that these changes were evident in the absence of an association with serum lipids, it would appear from the present investigation that abnormalities of axonal function are not related to serum triglyceride levels in type 2 diabetic patients. Moreover, although a previous study in a smaller cohort

Table 2. Axonal excitability parameters in patients vs controls.

| Parameter                      | Controls | T2DM | T2DM-NN |
|-------------------------------|----------|------|---------|
|                               | n = 42   | n = 71 | n = 20 |
| Latency (ms)                  | 6.9±0.2  | 7.2±0.1** | 7.0±0.2 |
| Stimulus response             |          |       |         |
| Stimulus for 50% of peak (mA)| 3.5±1.1  | 4.1±1.1 | 4.1±0.4 |
| Stimulus–response slope       | 4.5±1.1  | 4.2±1.0 | 4.6±0.3 |
| Strength duration relationship|          |       |         |
| SDTC (ms)                     | 0.4      | 0.5   | 0.4     |
| Rheobase (mA)                 | 2.4±1.1  | 2.7±1.1 | 2.7±0.3 |
| Threshold electrotonus        |          |       |         |
| TED(10–20ms)                  | 68.4±0.8 | 63.9±0.8*** | 64.5±1.6* |
| TEDpeak                       | 67.8±0.8 | 63.3±0.8*** | 64.2±1.5* |
| TED(undershoot)               | 22.7±0.5 | 19.2±0.4**** | 19.7±0.8** |
| TED(overshoot)                | -18.8±0.6 | -16.1±0.5** | -14.7±0.9*** |
| TEh(90–100ms)                 | -115.5±2.6 | -109.7±2.6 | -107.4±3.7 |
| Recovery cycle                |          |       |         |
| Relative refractory period (ms)| 3.2±0.1  | 3.4±0.1 | 3.3±0.2 |
| Superexcitability             | -22.5±0.9 | -17.5±0.8*** | -17.3±1.6** |
| Superexcitability at 5ms      | -22.1±1.0 | -16.4±1.1*** | -18.3±2.4* |
| Superexcitability 7ms         | -21.3±1.0 | -16.9±0.7*** | -17.6±1.4* |
| Subexcitability               | 13.8±0.5 | 11.2±0.5*** | 11.5±0.7* |
| Current threshold relationship|          |       |         |
| Resting slope                 | 0.6      | 0.6   | 0.6     |
| Minimum slope                 | 0.3      | 0.3   | 0.3     |

Excitability parameters from the type 2 diabetic patients compared to matched normal controls. Multiple abnormalities were noted in excitability parameters when comparing whole group data (T2DM) from the patients and controls. A subgroup of patients (n = 20) without clinical signs and symptoms of DPN (T2DM-NN) were also compared to controls revealing multiple abnormalities in axonal excitability. All recovery cycle and threshold electrotonus parameters are expressed as % change in threshold unless otherwise indicated. Significance is indicated by

*P<0.05
**P<0.005
***P<0.0005 and
****P<0.0001.

doi:10.1371/journal.pone.0153389.t002
suggested that triglyceride levels were associated with axonal dysfunction [15], the present study as well as the previous study assessed patients at a single time point and it is possible that a large cumulative level of exposure to elevated triglyceride concentrations is required before alterations in axonal function occur.

Previous clinical studies have indicated that dyslipidemia may represent a risk factor for neuropathy development in T2DM [33, 34]. Companion studies in vitro have invoked the possibility that hyperlipidemia in conjunction with hyperglycaemia may potentiate oxidative stress in dorsal root ganglion neurons, leading to mitochondrial injury and axonal degeneration [35–37]. However, in the present study, axonal function was assessed using axonal excitability techniques, which provide information on axonal biophysical properties at the site of stimulation [38], namely the nerve trunk. Excitability techniques do not assess proximal sensory and motor pathways and it is therefore possible that the lack of association suggests that the effects of hyperlipidemia are maximal at the level of the cell body, rather than the nerve trunk.

**Table 3. Linear Regression model between serum triglycerides and excitability parameters typically abnormal in type 2 diabetic patients.**

| Parameter                  | Adjusted* | p    | Sensitivity* | p  |
|----------------------------|-----------|------|--------------|----|
| SDTC (ms)                  | 0.01 (-0.03, 0.05) | 0.7  | 0.003 (-0.02, 0.027) | 0.83 |
| TEd(10–20ms)               | 1.2 (-1.4, 3.8) | 0.38 | 0.15 (-1.6, 1.9) | 0.87 |
| S2 accommodation           | 1.0 (-0.41, 2.4) | 0.16 | 0.94 (0.009, 1.9) | 0.05 |
| TEd(40–60ms)               | 0.32 (-1.7, 2.4) | 0.76 | -0.47 (-1.8, 0.88) | 0.49 |
| TEh(90–100ms)              | 3.2 (-6.5, 13) | 0.51 | 2.9 (-3.5, 9.4) | 0.36 |
| Superexcitability          | 2.4 (-0.049, 4.8) | 0.06 | 1.3 (-0.41, 2.9) | 0.14 |
| Subexcitability            | 0.85 (-0.46, 2.2) | 0.2  | 0.85 (-0.01, 1.7) | 0.05 |
| Superexcitability 7ms     | 2.3 (0.11, 4.5) | 0.04 | 1.2 (-0.26, 2.7) | 0.10 |

Linear Regression model between serum triglycerides and excitability parameters typically abnormal in type 2 diabetic patients. Model adjusted for neuropathy (TNS and TNG) and nephropathy severity (eGFR and CKD stage).

*Model adjusted for TNS and eGFR.

^ Model adjusted for TNG and CKD stage.
Moreover, previous studies have also suggested that aberrant Schwann cell physiology may exacerbate the development of neuropathy \[39, 40\] and this may not necessarily be reflected in altered axonal excitability parameters, which largely reflect properties of the axon itself rather than the myelin sheath. The lack of association also suggests that it is unlikely that acutely serum triglycerides have a direct effect on axonal biophysical properties, unlike other potential causes of axonal injury such as severe hyperkalaemia \[29\] or limb ischaemia \[27\], which are thought to directly impair axonal function by altering axonal biophysical properties \[27\].

It is likely that other mediating factors apart from hypertriglyceridaemia and hyperglycaemia may be involved in mediating neuropathy development in type 2 diabetes. Potential candidates include increased circulating inflammatory markers including NF-κB, which is upregulated in sural nerves in patients and rodent models \[41–43\] and involved in altered thermoneciception \[42\]. Furthermore, the pro-inflammatory cytokine TNF-α has been implicated in mechanical and thermal hyperalgesia in addition to ectopic firing of sensory neurons \[41, 

**Fig 2.** Scatter plots of patient triglyceride levels against excitability parameters. Triglyceride levels are plotted against axonal excitability parameters that are typically abnormal in type 2 diabetic patients: a) S2 accommodation and b) TEd(10–20ms) which are derived from the threshold electrotonus paradigm and provide indication on nodal and internodal ion channel activity; c) superexcitability and d) subexcitability which provide indication of paranodal and nodal K⁺ conductances respectively.

\[9.766.30.30\]
which occurs in a dose-dependent manner [41]. However a recent human study indicated no correlation between TNF-\(\alpha\) and nerve conduction velocities in type 2 diabetic patients [46]. Additionally, downstream mitochondrial dysfunction may also play a role in axonal dysfunction and has been proposed as an additive factor in diabetic neuropathy development [47]. Involved in appropriate cellular respiration, depolarisation of the mitochondrial membrane potential has been observed in DRG sensory neurons in animal models of diabetes and is prevented by insulin administration [48]. From a clinical perspective, the present study therefore suggests that treatment of triglyceride levels alone is unlikely to have any significant impact on axonal properties in T2DM. As axonal function may be involved in neuropathy progression [12], the findings suggest that preventing progression of neuropathy in T2DM may require investigation of other biochemical pathways. While elevated triglyceride levels may still be implicated in the development of small fibre neuropathy, future studies may have to explore other potential avenues of treatment such as control of inflammatory mediators in order to prevent progression of large fibre neuropathy in T2DM.

In summary, the present prospective study has demonstrated no association between changes in axonal function and triglyceride levels in a cohort of type 2 diabetic patients. Furthermore, prospective studies should consider evaluating additional factors in type 2 diabetic patients which may promote diabetic neuropathy, including the role of inflammatory markers which may mediate mitochondrial dysfunction.

### Acknowledgments

N. K. was supported by an Australian Postgraduate Award scholarship. A. K. was supported by a Career Development Fellowship of the National Health and Medical Research Council of Australia (#1065663). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Author Contributions

Conceived and designed the experiments: NK CB AP AK. Performed the experiments: NK WN AP AK. Analyzed the data: NK CB AK. Contributed reagents/materials/analysis tools: AP AK. Wrote the paper: NK WN AP CB AK.
References

1. Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009; 35(3):206–13. doi: 10.1016/j.diabet.2008.11.004 PMID: 19297223

2. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009; 27(2):95–112. Epub 2009/03/04. doi: 10.2165/00019053-200927020-00002 PMID: 19254044.

3. Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst. 2012; 17(s2):22–7.

4. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837–53. Epub 1998/09/22. PMID: 9742976.

5. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376(9739):419–30. Epub 2010/07/03. doi: 10.1016/s0140-6736(10)60576-4 PMID: 20594588; PubMed Central PMCID: PMC3412333.

6. Charles M, Fleischer J, Witte DR, Ejskjaer N, Borch-Johnsen K, Lauritzen T, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia. 2013; 56(1):101–8. doi: 10.1007/s00125-012-2744-5 PMID: 23064291.

7. The Diabetes Control and Complications Research Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977–86. Epub 1993/09/30. doi: 10.1056/NEJM199305303291401 PMID: 8366922.

8. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology. 2012; 11(6):521–34. doi: http://dx.doi.org/10.1016/S1474-4422(12)70065-0 PMID: 22608666.

9. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2012; 17(s2):22–7. doi: 10.1007/s11596-012-0735-4 PMID: 22522615.

10. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology. 2012; 11(6):521–34. doi: http://dx.doi.org/10.1016/S1474-4422(12)70065-0 PMID: 22608666.

11. Krishnan AV, Lin CS, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol. 2009; 89(3):288–313. Epub 2009/08/25. doi: 10.1016/j.pneurobio.2009.08.002 PMID: 19699774.

12. Sung JY, Park SB, Liu YT, Kwai N, Arnold R, Krishnan AV, et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes. 2012; 61(6):1592–8. Epub 2012/04/24. doi: 10.2337/db11-1509 PMID: 22522615; PubMed Central PMCID: PMC3357264.

13. Arnold R, Kwai N, Lin CS, Poynten AM, Kiernan MC, Krishnan AV. Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes Metab Res Rev. 2013; 29(1):53–9. Epub 2012/09/26. doi: 10.1002/dmrr.2360 PMID: 23080000.

14. Krishnan AV, Lin CS, Kiernan MC. Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain. 2008; 131(Pt 5):1209–16. Epub 2008/03/26. doi: 10.1093/brain/awn052 PMID: 18362098.

15. Kikkawa Y, Kujawa S, Misawa S, Tamura N, Kitano Y, Ogawara K, et al. The acute effects of glycemic control on nerve conduction in human diabetics. Clin Neurophysiol. 2005; 116(2):270–4. Epub 2005/01/22. doi: 10.1016/j.clinph.2004.08.011 PMID: 15661104.

16. Bae JS, Kim OK, Kim JM. Altered nerve excitability in subclinical/early diabetic neuropathy: evidence for early neurovascular process in diabetes mellitus? Diabetes Res Clin Pract. 2011; 91(2):183–9. Epub 2010/12/07. doi: 10.1016/j.diabres.2010.11.008 PMID: 21130514.

17. Misawa S, Kuwabara S, Ogawara K, Kitano Y, Yagui K, Hattori T. Hyperglycemia alters refractory periods in human diabetic neuropathy. Clin Neurophysiol. 2004; 115(11):2525–9. Epub 2004/10/07. doi: 10.1016/j.clinph.2004.06.008 PMID: 15465442.

18. Bae JS, Kim BJ. Subclinical diabetic neuropathy with normal conventional electrophysiological study. J Neurol. 2007; 254(1):53–9. Epub 2007/05/18. doi: 10.1007/s00415-006-0261-5 PMID: 17508139.

19. Combleth DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology. 1999; 53(8):1660–4. Epub 1999/11/24. PMID: 10563609.
20. Kwai NC, Arnold R, Wickremaarachchi C, Lin CS, Poynten AM, Kiernan MC, et al. Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes. Diabetes Care. 2013; 36(5):1272–7. Epub 2013/02/14. doi: 10.2337/dc12-1310 PMID: 23404298; PubMed Central PMCID: PMC3631837.

21. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol. 2001; 112(9):1575–85. Epub 2001/08/22. PMID: 11514239.

22. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000; 23(3):399–409. Epub 2000/02/19. PMID: 10679717.

23. Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol. 1997; 498 (Pt 1):277–94. Epub 1997/01/01. PMID: 9023784; PubMed Central PMCID: PMCPmc1159250.

24. Bostock H. The strength-duration relationship for excitation of myelinated nerve: computed dependence on membrane parameters. J Physiol. 1983; 341:59–74. Epub 1983/08/01. PMID: 6312032; PubMed Central PMCID: PMC1195322.

25. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of human peripheral nerve. Brain. 1996; 119 (Pt 2)(Pt 2):439–47. Epub 1996/04/01. PMID: 8800939.

26. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012; 28(S1):8–14.

27. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000; 123 Pt 12(Pt 12):2542–51. Epub 2000/12/02. PMID: 11099455.

28. Greene DA, Lattimer SA. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Muscle Nerve. 1998; 21(2):137–41. PMID: 9500147.

29. Arnold R, Russell BA, Howells J, Grinius V, Kiernan MC, Lin CS, et al. Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clin Neurophysiol. 2014; 125(1):179–85. Epub 2013/07/23. doi: 10.1016/j.clinph.2013.06.022 PMID: 23967066.

30. Arnold R, Russell BA, Planta TJ, Grinius V, Lin CS, Kiernan MC, et al. Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PLoS one. 2013; 8(3):e59055. doi: 10.1371/journal.pone.0059055 PMID: 23536855

31. Vas PR, Sharma S, Rayman G. LDIflare small fiber function in normal glucose tolerant subjects with type 2 diabetes. J Diab Complicat. 2013; 27:436–442. doi: 10.1016/j.jdiacomp.2013.04.003 PMID: 23731827

32. Smith AG, Singleton JR (2013) Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. Journal of Diabetes and its Complications 27: 436–442. doi: 10.1016/j.jdiacomp.2013.04.003

33. Gæde P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383–93. PMID: 12556541

34. Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008; 51(4):562–6. doi: 10.1007/s00125-007-0919-2 PMID: 18193189

35. Padilla A, Descorbeth M, Almeyda AL, Payne K, De Leon M. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res. 2011; 1370(0):64–73. doi: http://dx.doi.org/10.1016/j.brainres.2011.10.013.

36. Lupachyk S, Watcho P, Hasanova N, Julius U, Obrosova IG. Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative–nitrosative stress. Free Radic Biol Med. 2012; 52(8):1255–63. doi: http://dx.doi.org/10.1016/j.freeradbiomed.2012.01.029 PMID: 22366714

37. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011; 7(10):573–83. Epub 2011/09/14. doi: 10.1038/nrneurol.2011.137 PMID: 21912405.

38. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998; 21(2):137–58. Epub 1998/02/18. PMID: 9466589.

39. Viader A, Sasaki Y, Kim S, Strickland A, Workman Cayce S, Yang K, et al. Aberrant Schwann Cell Lipid Metabolism Linked to Mitochondrial Deficits Leads to Axon Degeneration and Neuropathy. Neuron. 2013; 77(5):886–98. doi: http://dx.doi.org/10.1016/j.neuron.2013.01.012 PMID: 23473519

40. Becker M, Benromano T, Shahar A, Nevo Z, Pick C. Changes in the Basal Membrane of Dorsal Root Ganglia Schwann Cells Explain the Biphasic Pattern of the Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats. J Mol Neurosci. 2014; 54(4):704–13. doi: 10.1007/s12031-014-0424-2 PMID: 25260693

41. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport. 1996; 7(18):2897–901. Epub 1996/11/25. PMID: 916205.
42. Bierhaus A, Haslbeck K-M, Humpert PM, Lilienziek B, Dehmer T, Morcos M, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest. 2004; 114(12):1741–51. doi: 10.1172/JCI200418058 PMID: PMC535062.

43. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab. 2008; 93(2):578–83. Epub 2007/11/22. doi: 10.1210/jc.2007-2185 PMID: 18029454; PubMed Central PMCID: PMCPmc2243229.

44. Purwata TE. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res. 2011; 4:169–75. Epub 2011/08/04. doi: 10.2147/jpr.s21751 PMID: 21811392; PubMed Central PMCID: PMCPmc3141833.

45. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience. 1997; 81(1):255–62. Epub 1997/09/23. PMID: 9300418.

46. Duksal T, Tiftikcioglu B, Bilgin S, Kose S, Zorlu Y. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand. 2015. Epub 2015/09/09. doi: 10.1111/ane.12474 PMID: 26346888.

47. Fernyhough P. Mitochondrial Dysfunction in Diabetic Neuropathy: a Series of Unfortunate Metabolic Events. Curr Diab Rep. 2015; 15(11):89. Epub 2015/09/16. doi: 10.1007/s11892-015-0671-9 PMID: 26370700.

48. Huang TJ, Price SA, Chilton L, Calcutt NA, Tomlinson DR, Verkhratsky A, et al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes. 2003; 52(8):2129–36. Epub 2003/07/29. PMID: 12882932.